Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.